Table 1 Baseline characteristics of enrolled diabetic patients from 2014, 2015 and 2018 (N = 61,004)
Year | 2014 | 2015 | 2018 | Â |
|---|---|---|---|---|
Characteristics | n(%) | n(%) | n(%) | p-value |
No. of participants | 17,761 | 18,551 | 24,692 | Â |
Age (year) |  |  |  | < 0.001 |
< 60 | 9,217 (51.9) | 9,281 (50) | 11,656 (47.2) |  |
≥ 60 | 8,544 (48.1) | 9,270 (50) | 13,036 (52.8) |  |
Sex |  |  |  | < 0.001 |
Male | 5,211 (29.3) | 5,805 (31.3) | 8,017 (32.5) | Â |
Female | 12,550 (70.7) | 12,746 (68.7) | 16,675 (67.5) | Â |
Scheme |  |  |  | < 0.001 |
Universal healthcare coverage | 1,4037 (79.2) | 14,365 (77.4) | 19,432 (78.7) | Â |
Civil servant medical benefit | 2,641 (14.9) | 3,024 (16.3) | 3,807 (15.4) | Â |
Social security | 827 (4.7) | 804 (4.3) | 1,129 (4.6) | Â |
Others | 224 (1.3) | 358 (1.9) | 324 (1.3) | Â |
BMI (kg/m2) |  |  |  | < 0.001 |
< 25 | 8,471 (47.7) | 8,546 (46.1) | 11,283 (45.7) |  |
≥ 25 | 9,290 (52.3) | 10,005 (53.9) | 13,409 (54.3) |  |
Hypertension | 13,080 (73.6) | 14,182 (76.4) | 18,638 (75.5) | < 0.001 |
Dyslipidemia | 12,524 (70.5) | 13,854 (74.7) | 17,677 (71.6) | < 0.001 |
Gout | 592 (3.3) | 635 (3.4) | 1,198 (4.9) | < 0.001 |
Receiving anti-diabetic drug | 17,337 (97.6) | 18,022 (97.1) | 23,926 (96.9) | < 0.001 |
FPG (mg/dL) |  |  |  | < 0.001 |
≤ 130 | 6,542 (29.3) | 6,860 (30.7) | 8,920 (40) |  |
> 130 | 11,219 (29) | 11,691 (30.2) | 15,772 (40.8) |  |
TG/HDL ratio | Â | Â | Â | Â |
median (IQR) | 3.3 (2.2–5.1) | 3.2 (2.1-5.0) | 3.0 (2.0-4.7) | < 0.001 |
Quartile 1 (< 2.05) | 4,080 (23.0) | 4,842 (26.1) | 7,022 (28.4) | < 0.001 |
Quartile 2 (2.05–3.16) | 4,382 (24.7) | 4,495 (24.2) | 6,109 (24.7) |  |
Quartile 3 (3.16–4.91) | 4,452 (25.1) | 4,443 (24) | 5,850 (23.7) |  |
Quartile 4 (> 4.91) | 4,847 (27.3) | 4,771 (25.7) | 5,711 (23.1) |  |